Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients.

Author information

Affiliations

  • 1. Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.
      Authors
    • Oyaert M 1
    • Padalko E 1
    (2 authors)
  • 2. Department of General Internal Medicine, Ghent University Hospital, Ghent, Belgium.
      Authors
    • De Scheerder MA 2
    • Van Herrewege S 2
    (2 authors)
  • 3. Department of Neurology, Ghent University Hospital, Ghent, Belgium.
      Authors
    • Laureys G 3
    • Van Assche S 3
    (2 authors)
  • 4. Department of Neurology, AZ Sint-Jan Brugge Oostende, Brugge, Belgium.
      Authors
    • Cambron M 4
    (1 author)
  • 5. Department of Internal Medicine and Paediatrics, Ghent University Hospital, Ghent, Belgium.
      Authors
    • Naesens L 5
    • Hoste L 5
    • Claes K 5
    • Haerynck F 5
    (4 authors)
    • Show all (8)

ORCIDs linked to this article

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 13 Nov 2023, 43(1):177-185
https://doi.org/10.1007/s10096-023-04701-x PMID: 37953413 

Abstract 

We assessed the humoral and cellular immune responses after two booster mRNA vaccine administrations [BNT162b2 (Pfizer-BioNTech vaccine)] in cohorts of immunocompromised patients (n = 199) and healthy controls (HC) (n = 54). All patients living with HIV (PLWH) and chronic kidney disease (CKD) patients and almost all (98.2%) of the primary immunodeficiency (PID) patients had measurable antibodies 3 and 6 months after administration of the third and fourth vaccine dose, comparable to the HCs. In contrast, only 53.3% and 83.3% of the multiple sclerosis (MS) and rheumatologic patients, respectively, developed a humoral immune response. Cellular immune response was observed in all PLWH after administration of four vaccine doses. In addition, cellular immune response was positive in 89.6%, 97.8%, 73.3% and 96.9% of the PID, MS, rheumatologic and CKD patients, respectively. Unlike the other groups, only the MS patients had a significantly higher cellular immune response compared to the HC group. Administration of additional vaccine doses results in retained or increased humoral and cellular immune response in patients with acquired or inherited immune disorders.

Full text links 

Read article at publisher's site: https://doi.org/10.1007/s10096-023-04701-x

References 

Articles referenced by this article (27)

Show 10 more references (10 of 27)

Citations & impact 

Impact metrics

3
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/156397516
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/156397516

Article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.